Cited by 77Lymphatic System and DiseasesHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Reduced lymphatic reserve in heart failure with preserved ejection fraction

Open access
Rossitto, Giacomo, Mary, Sheon, McAllister, Christine, Neves, Karla Bianca, Haddow, Laura, Rocchiccioli, John Paul, Lang, Ninian Nicholas, Murphy, Clare Louise +3 more·2020·Journal of the American College of Cardiology

Abstract

Microvascular dysfunction plays an important role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). However, no mechanistic link between systemic microvasculature and congestion, a central feature of the syndrome, has yet been investigated. This study aimed to investigate capillary–interstitium fluid exchange in HFpEF, including lymphatic drainage and the potential osmotic forces exerted by any hypertonic tissue Na+ excess. Patients with HFpEF and healthy control subjects of similar age and sex distributions (n = 16 per group) underwent: 1) a skin biopsy for vascular immunohistochemistry, gene expression, and chemical (water, Na+, and K+) analyses; and 2) venous occlusion plethysmography to assess peripheral microvascular filtration coefficient (measuring capillary fluid extravasation) and isovolumetric pressure (above which lymphatic drainage cannot compensate for fluid extravasation). Skin biopsies in patients with HFpEF showed rarefaction of small blood and lymphatic vessels (p = 0.003 and p = 0.012, respectively); residual skin lymphatics showed a larger diameter (p = 0.007) and lower expression of lymphatic differentiation and function markers (LYVE-1 [lymphatic vessel endothelial hyaluronan receptor 1]: p < 0.05; PROX-1 [prospero homeobox protein 1]: p < 0.001) compared with control subjects. In patients with HFpEF, microvascular filtration coefficient was lower (calf: 3.30 [interquartile range (IQR): 2.33 to 3.88] l × 100 ml of tissue–1 × min–1 × mm Hg–1 vs. 4.66 [IQR: 3.70 to 6.15] μl × 100 ml of tissue–1 × min–1 × mm Hg–1; p < 0.01; forearm: 5.16 [IQR: 3.86 to 5.43] l × 100 ml of tissue–1 × min–1 × mm Hg–1 vs. 5.66 [IQR: 4.69 to 8.38] μl × 100 ml of tissue–1 × min–1 × mm Hg–1; p > 0.05), in keeping with blood vascular rarefaction and the lack of any observed hypertonic skin Na+ excess, but the lymphatic drainage was impaired (isovolumetric pressure in patients with HFpEF vs. control subjects: calf 16 ± 4 mm Hg vs. 22 ± 4 mm Hg; p < 0.005; forearm 17 ± 4 mm Hg vs. 25 ± 5 mm Hg; p < 0.001). Peripheral lymphatic vessels in patients with HFpEF exhibit structural and molecular alterations and cannot effectively compensate for fluid extravasation and interstitial accumulation by commensurate drainage. Reduced lymphatic reserve may represent a novel therapeutic target.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.10.022

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Altered lymphatic function contributes to subclinical edema that can compromise organ function in conditions including heart failure with preserved ejection fraction and diseases associated with excess tissue sodium storage.

    “Recent studies suggest that altered lymphatic function contributes to subclinical edema that can compromise organ function under conditions that include heart failure with preserved ejection fraction (132) and diseases associated with excess tissue sodium storage (133).”

    From Transport and Immune Functions of the Lymphatic System. (2025) · cites this paper as [132]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. [1]Benjamin E.J. Virani S.S. Callaway C.W. Heart Disease and Stroke Statistics-2018 Update: a report from the American Heart Association Circulation 137 2018 e67 e492 29386200
  2. [2]Chang P.P. Wruck L.M. Shahar E. Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC study community surveillance Circulation 138 2018 12 24 29519849 PMC6030442
  3. [3]Campbell R.T. Jhund P.S. Castagno D. Hawkins N.M. Petrie M.C. McMurray J.J. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 60 2012 2349 2356 23141494
  4. [4]Borlaug B.A. Melenovsky V. Russell S.D. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction Circulation 114 2006 2138 2147 17088459
  5. [5]Pfeffer M.A. Shah A.M. Borlaug B.A. Heart failure with preserved ejection fraction in perspective Circ Res 124 2019 1598 1617 31120821 PMC6534165
  6. [8]D'Amario D. Migliaro S. Borovac J.A. Microvascular dysfunction in heart failure with preserved ejection fraction Front Physiol 10 2019 1347 31749710 PMC6848263
  7. [10]Haykowsky M.J. Brubaker P.H. John J.M. Stewart K.P. Morgan T.M. Kitzman D.W. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction J Am Coll Cardiol 58 2011 265 274 21737017 PMC3272542
  8. [11]Kitzman D.W. Nicklas B. Kraus W.E. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction Am J Physiol Heart Circ Physiol 306 2014 H1364 H1370 24658015 PMC4010668
  9. [12]Dhakal B.P. Malhotra R. Murphy R.M. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction Circ Heart Fail 8 2015 286 294 25344549 PMC5771713
  10. [13]Kitzman D.W. Upadhya B. Vasu S. What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction Circulation 131 2015 522 524 25552355 PMC4792113
  11. [14]Titze J. Lang R. Ilies C. Osmotically inactive skin Na+ storage in rats Am J Physiol Renal Physiol 285 2003 F1108 F1117 12888617
  12. [15]Machnik A. Neuhofer W. Jantsch J. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism Nat Med 15 2009 545 552 19412173
  13. [16]Kopp C. Linz P. Dahlmann A. 23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients Hypertension 61 2013 635 640 23339169
  14. [17]Karg M.V. Bosch A. Kannenkeril D. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial Cardiovasc Diabetol 17 2018 5 29301520 PMC5753452
  15. [19]Ponikowski P. Voors A.A. Anker S.D. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur Heart J 37 2016 2129 2200 27206819
  16. [20]Rossitto G. Mary S. Chen J.Y. Tissue sodium excess is not hypertonic and reflects extracellular volume expansion Nat Commun 11 2020 4222 32839436 PMC7445299
  17. [21]Gamble J. Gartside I.B. Christ F. A reassessment of mercury in silastic strain gauge plethysmography for microvascular permeability assessment in man J Physiol 464 1993 407 422 8229810 PMC1175393
  18. [22]Wilkinson I.B. Webb D.J. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications Br J Clin Pharmacol 52 2001 631 646 11736874 PMC2014568
  19. [23]Gamble J. Realisation of a technique for the non-invasive, clinical assessment of microvascular parameters in man; the KM factor Eur Surg Res 34 2002 114 123 11867911
  20. [24]Stewart J.M. Microvascular filtration is increased in postural tachycardia syndrome Circulation 107 2003 2816 2822 12756156
  21. [25]Bauer A. Christ F. Gamble J. Can lymphatic drainage be measured non-invasively in human limbs, using plethysmography? Clin Sci 106 2004 627 633 14763898
  22. [26]Mohanakumar S. Telinius N. Kelly B. Morphology and function of the lymphatic vasculature in patients with a Fontan circulation Circ Cardiovasc Imaging 12 2019 e008074 30943769
  23. [27]Srinivasan R.S. Oliver G. Prox1 dosage controls the number of lymphatic endothelial cell progenitors and the formation of the lymphovenous valves Genes Dev 25 2011 2187 2197 22012621 PMC3205588
  24. [28]Cha B. Geng X. Mahamud M.R. Complementary Wnt sources regulate lymphatic vascular development via PROX1-dependent Wnt/beta-catenin signaling Cell Rep 25 2018 571 584.e5 30332639 PMC6264919
  25. [29]Henri O. Pouehe C. Houssari M. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction Circulation 133 2016 1484 1497 26933083
  26. [30]Fearon W.F. Balsam L.B. Farouque H.M. Novel index for invasively assessing the coronary microcirculation Circulation 107 2003 3129 3132 12821539
  27. [31]Pries A.R. Reglin B. Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur Heart J 38 2017 478 488 26843279 PMC5381591
  28. [32]Levick J.R. Michel C.C. Microvascular fluid exchange and the revised Starling principle Cardiovasc Res 87 2010 198 210 20200043
  29. [34]Mortimer P.S. Rockson S.G. New developments in clinical aspects of lymphatic disease J Clin Invest 124 2014 915 921 24590276 PMC3938261
  30. [35]Escobedo N. Oliver G. The lymphatic vasculature: its role in adipose metabolism and obesity Cell Metab 26 2017 598 609 28844882 PMC5629116
  31. [36]Scallan J.P. Hill M.A. Davis M.J. Lymphatic vascular integrity is disrupted in type 2 diabetes due to impaired nitric oxide signalling Cardiovasc Res 107 2015 89 97 25852084 PMC4490202
  32. [37]Stanton A.W. Modi S. Bennett Britton T.M. Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment Breast Cancer Res Treat 117 2009 549 557 19052859
  33. [38]Burnand K.M. Glass D.M. Mortimer P.S. Peters A.M. Lymphatic dysfunction in the apparently clinically normal contralateral limbs of patients with unilateral lower limb swelling Clin Nucl Med 37 2012 9 13 22157021
  34. [39]Witte M.H. Dumont A.E. Clauss R.H. Rader B. Levine N. Breed E.S. Lymph circulation in congestive heart failure: effect of external thoracic duct drainage Circulation 39 1969 723 733 5785287
  35. [40]Telinius N. Mohanakumar S. Majgaard J. Human lymphatic vessel contractile activity is inhibited in vitro but not in vivo by the calcium channel blocker nifedipine J Physiol 592 2014 4697 4714 25172950 PMC4253471

Cited by

Sorted by citations

Authors
Rossitto, G., Mary, S., McAllister, C., Neves, K. B., Haddow, L., Rocchiccioli, J. P., Lang, N. N., Murphy, C. L., Touyz, R. M., Petrie, M. C., & Delles, C.
Affiliations
  • University of Padua (IT)
  • University of Glasgow (GB)
  • Queen Elizabeth University Hospital (GB)
  • Royal Alexandra Hospital (GB)
  • Golden Jubilee National Hospital (GB)
Corresponding author
Rossitto, Giacomo
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2020-12
Volume
76
Issue
24
Pages
2817-2829
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3111587775
Cited by
77
References
5
Citations by year
2026: 8 · 2025: 13 · 2024: 17 · 2023: 13 · 2022: 13 · 2021: 12 · 2020: 1
FWCI
3.52
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
Funders
British Heart Foundation
Topics
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure with preserved ejection fraction, lymphatic drainage, venous occlusion plethysmography, skin biopsy, LYVE-1, Prox1, microvascular dysfunction, osmotic pressure, sodium excess, skin microcirculation, venous congestion
MeSH terms
Aged, Female, Heart Failure, Humans, Male, Middle Aged, Skin, Sodium, Stroke Volume, Case-Control Studies, Lymphatic Vessels, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review